L-Ornithine L-Aspartate(L-Ornithine-L-Aspartate) - Uses, Dosage and Side Effects
L-Ornithine L-Aspartate(L-Ornithine-L-Aspartate) - Uses, Dosage and Side Effects
L-Ornithine-L-Aspartate (LOLA) for dogs and cats combines the amino acids L-Ornithine and L-Aspartate. Veterinarians may use it as an ammonia-lowering adjunct to help manage high blood ammonia levels, particularly in pets with liver disease and hepatic encephalopathy.
LOLA is not a routine liver supplement for every dog or cat with abnormal liver enzymes. Its use depends on the underlying condition, blood ammonia levels, neurological signs, liver function, and the veterinarian's overall treatment plan.
L-Ornithine-L-Aspartate supports the body's natural mechanisms for ammonia detoxification. L-Ornithine participates in the urea cycle, which converts ammonia into urea for elimination. L-Aspartate can contribute to metabolic pathways involved in ammonia detoxification and glutamine formation
This may be particularly useful when liver disease reduces the body’s ability to clear ammonia effectively.
In cats, L-Ornithine-L-Aspartate is expected to work through the same ammonia-detoxifying pathways. It may help support the conversion of ammonia into urea and glutamine when ammonia accumulates because of impaired hepatic detoxification or other metabolic problems.
However, there is considerably less direct clinical research on LOLA in cats. Therefore, a vet should determine its use and dose on a case-by-case basis.
L-Ornithine-L-Aspartate dosage for dogs is weight-based and typically administered orally, either as granules dissolved in water or as a liquid formulation mixed into food. Giving it with a meal reduces the risk of gastrointestinal upset. Your vet determines the dose and frequency based on the severity of hepatic disease, the degree of ammonia elevation, and clinical response. Do not adjust the dose without veterinary guidance, as ammonia dysregulation can worsen rapidly with inadequate dosing.
Kittens with hepatic abnormalities require a thorough diagnostic evaluation before starting LOLA. Portosystemic shunts are among the more common congenital liver conditions diagnosed in young cats. Dosing requires precise weight measurement and close follow-up to monitor ammonia levels, neurological status, and growth.
Side effects are uncommon at recommended doses.
Possible side effects in dogs include:
Persistent gastrointestinal upset should prompt dose review and veterinary advice
L-Ornithine-L-Aspartate for dogs and cats is a clinically meaningful hepatoprotective compound for managing high ammonia levels in hepatic disease. It supports the urea cycle and glutamine synthesis, helping reduce blood ammonia and its neurological consequences.
Consistent, accurate weight-based dosing, dietary protein management, and regular blood monitoring are essential for effective long-term use. LOLA works best as part of a comprehensive hepatic management plan under ongoing veterinary supervision.
Ahn, J.-O., Li, Q., Lee, Y.-H., Han, S.-M., Hwang, C.-Y., Youn, H.-Y., & Chung, J.-Y. (2016). Hyperammonemic hepatic encephalopathy management through L-Ornithine-L-Aspartate administration in dogs. Journal of Veterinary Science, 17(3), 431–431. https://vetsci.org/DOIx.php?id=10.4142/jvs.2016.17.3.431
Center, S. A. (n.d.). Hepatic encephalopathy in small animals. In MSD Veterinary Manual. Retrieved 19 August 2026, from https://www.msdvetmanual.com/digestive-system/hepatic-disease-in-small-animals/hepatic-encephalopathy-in-small-animals
Twedt, D. C. (2025). Clinical nutrition for common liver diseases 2. In VIN. https://www.vin.com/apputil/content/defaultadv1.aspx?pId=12886&catId=57100&id=7054653